4%) than any of the ALVESCO treatment groups (ciclesonide 80 mcg
BID: n=4, 2.
Since 2001, MCG
has reported solid profitability with return on managed assets consistently above 4.
Edwards, of MCG
Capital Corporation, +1-703-247-7502, or Sedwards@MCGCapital.
909 patients were treated for 6 months with either 500 mcg
roflumilast once daily or placebo.
We look forward to building on this new relationship with MCG
utilizing GENICOM's superior service capabilities in providing service solutions in the workstations, personal computers, monitors, storage devices and printers marketplace.
FONS' FDH product offering selected by MCG
includes 144-fiber and 216-fiber configured enclosures, available in either pole or pad mounting arrangements for aerial or below grade deployment applications.
won the Grand Award for the Best Rehabilitated Commercial or Industrial Project in the Commercial/Industrial category.
the fastest-growing provider of performance analysis products and services for Global 2000 networks, announced Monday a reseller agreement with MCG
Software A/S (MCG
), a Copenhagen, Denmark-based provider of software and service solutions to large and mid-sized companies.
For patients this means improved access to specialists at MCG
, often without leaving their hometown.
In a 12-week study comparing Alvesco(R) with fluticasone propionate, 697 patients 12-75 years of age, with persistent asthma, received either one inhalation of Alvesco(R) 80 mcg
or Alvesco(R) 160 mcg
in the evening, or inhalations of fluticasone propionate 88 mcg
in both the morning and evening (fluticasone propionate total daily dose 176 mcg
3, 2015 /PRNewswire/ -- WiserTogether, who offers data-driven treatment transparency solutions to employers, health plans and payers, and MCG
, the trusted provider of informed care strategies for healthcare organizations, today announced that MCG
's leading evidence-based guideline content will be added to WiserTogether's suite of solutions, including Wiser Health.
Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that investigational once-daily dual bronchodilator QVA149 (indacaterol maleate 110 mcg
/ glycopyrronium 50 mcg
) was more effective at reducing all chronic obstructive pulmonary disease (COPD) exacerbations compared to glycopyrronium 50 mcg
and open-label (OL) tiotropium 18 mcg
a treatment with established efficacy in preventing exacerbations.